Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost.

Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost. Abstract Text:

James S Welsh,Jeffrey P Limmer,

PURPOSE: Standard radiation for early breast cancer requires daily treatment for 6 to 7 weeks. This is an inconvenience to many women, and for some a barrier for breast conservation. We present the acute toxicity of a 4-week course of hypofractionated radiation. METHODS AND MATERIALS: A total of 75 patients completed radiation on a Phase II trial approved by the hospital institutional review board. Eligibility criteria were broad to include any patient normally eligible for standard radiation: age >or=18 years, invasive or in situ cancer, American Joint Committee on Cancer Stage 0 to II, breast-conserving surgery, and any systemic therapy not given concurrently. The median age was 52 years (range, 31-81 years). Of the patients, 15% had ductal carcinoma in situ, 67% T1, and 19% T2; 71% were N0, 17% N1, and 12% NX. Chemotherapy was given before radiation in 44%. Using photon intensity-modulated radiation therapy and incorporated electron beam boost, the whole breast received 45 Gy and the lumpectomy bed 56 Gy in 20 treatments over 4 weeks. RESULTS: The maximum acute skin toxicity by the end of treatment was Grade 0 in 9 patients (12%), Grade 1 in 49 (65%) and Grade 2 in 17 (23%). There was no Grade 3 or higher skin toxicity. After radiation, all Grade 2 toxicity had resolved by 6 weeks. Hematologic toxicity was Grade 0 in most patients except for Grade 1 neutropenia in 2 patients, and Grade 1 anemia in 11 patients. There were no significant differences in baseline vs. 6-week posttreatment patient-reported or physician-reported cosmetic scores. CONCLUSIONS: This 4-week course of postoperative radiation using intensity-modulated radiation therapy is feasible and is associated with acceptable acute skin toxicity and quality of life. Long-term follow-up data are needed. This radiation schedule may represent an alternative both to longer 6-week to 7-week standard whole-breast radiation and more radically shortened 1-week, partial-breast treatment schedules.

Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost. Publishing Authors By Initials

JS Welsh,JP Limmer,

For similar relative biological effectiveness research abstracts see: relative biological effectiveness research

PUBMED ID PMID:

MEDLINE DATE:

Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: International journal of radiation oncology, biolo

VOLUME: 68

Page Numbers: 347-53

Journal Abbreviation: Int. J. Radiat. Oncol. Biol. P

ISSN: 0360-3016

DAY: 26

MONTH: 03

YEAR: 2007

Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7603616

Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost. Keywords Mesh Terms:

KEYWORDS: Relative Biological Effectiveness

MESH TERMS: methods

Chemical & Substance for Abstract: Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost.

AFFILIATION: Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. Gary.Freedman@FCCC.edu

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Int J Radiat Oncol Biol Phys

REFSOURCE: Int J Radiat Oncol Biol Phys. 2007 Nov 1

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost Related Publications

• AT-rich repeats associated with chromosome 22q11.2 rearrangement disorders shape human genome architecture on Yq12.
• Analysis of the replication of HIV-1 forced to use tRNAMet(i) supports a link between primer selection, translation and encapsidation.
• Assessment of cancer-related fatigue: implications for clinical diagnosis and treatment.
• Associations between Health-related Physical Fitness and Physical Activity Participation in Elementary School Children in Hong Kong: 2234: Board #147 June 1 9:00 AM - 10:30 AM.
• Behavioral interventions in treating anticipatory nausea and vomiting.
• Calculous diseases in infants and children.
• Cancer-related fatigue: causes, consequences, and management.
• Cancer-related fatigue: the scale of the problem.
• Clinician-Patient Communication about Physical Activity in an Underserved Population: 762: May 31 4:00 PM 4:15 PM.
• Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy?
• Dissection of Tbx1 and Fgf interactions in mouse models of 22q11DS suggests functional redundancy.
• Effects of vitamin E on oxidative stress and atherosclerosis in an obese hyperlipidemic mouse model.
• Expression of epithelial mucins Muc1, Muc2, and Muc3 in ductal carcinoma in situ of the breast.
• Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost.
• Hypothalamic-pituitary-adrenal axis and ethanol modulation of deoxycorticosterone levels in cynomolgus monkeys.
• Impact of forced selection of tRNAs on HIV-1 replication and genome stability highlight preferences for selection of certain tRNAs.
• Importance of A-loop complementarity with tRNAHis anticodon for continued selection of tRNAHis as the HIV reverse transcription primer.
• Mutations in GJB2, GJB6, and mitochondrial DNA are rare in African American and Caribbean Hispanic individuals with hearing impairment.
• Mutations in the TPsiC loop of E. coli tRNALys,3 have varied effects on in trans complementation of HIV-1 replication.
• Neuropsychological function and employment status in a welfare-to-work sample.
• Nucleotides within the anticodon stem are important for optimal use of tRNA(Lys,3) as the primer for HIV-1 reverse transcription.
• Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions.
• Patterns and correlates of patient referral to surgeons for treatment of breast cancer.
• Quantification of F2-isoprostanes as a biomarker of oxidative stress.
• Seminal selenium concentrations and spermatozoal abnormalities in beef bulls.
• Sequential degradation of alphaII and betaII spectrin by calpain in glutamate or maitotoxin-stimulated cells.
• Structure of the calmodulin alphaII-spectrin complex provides insight into the regulation of cell plasticity.
• The role of Haemophilus somnus in early embryonic death. I. The effect of the organism on embryos by day 8 postbreeding.
• Urinary prostaglandin F2alpha is generated from the isoprostane pathway and not the cyclooxygenase in humans.
• tRNA isoacceptor preference prior to retrovirus Gag-Pol junction links primer selection and viral translation.